Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
The THAG regimen as preoperative therapy showed encouraging clinical activity with a manageable safety profile. Dynamic biomarker findings reveal potential for guiding precision treatment strategies with THAG.
Authors
- Baorui Liu (ORCID: https://orcid.org/0000-0002-2539-7732)
- Li AiMei (ORCID: https://orcid.org/0009-0003-2020-8909)
- Bozhu Chen (ORCID: https://orcid.org/0000-0003-0977-2616)
- Fukuoka Tong (ORCID: https://orcid.org/0009-0009-2192-3377)
- Xing Zhang (ORCID: https://orcid.org/0009-0004-9133-6833)
- Qing Gu (ORCID: https://orcid.org/0000-0002-1112-790X)
- Min Tang (ORCID: https://orcid.org/0009-0002-1619-1983)
- Juan Du (ORCID: https://orcid.org/0009-0001-8477-573X)
- Liang Mao (ORCID: https://orcid.org/0000-0002-7112-9421)
- X. H. Bai (ORCID: https://orcid.org/0009-0006-9737-2880)
- Zhongyu Lu (ORCID: https://orcid.org/0009-0000-6813-7650)
- Weiwei Kong (ORCID: https://orcid.org/0009-0001-8342-0638)
- Qi Li (ORCID: https://orcid.org/0009-0006-4215-1781)
- Gang Li (ORCID: https://orcid.org/0009-0002-1292-1723)
- Jun Chen (ORCID: https://orcid.org/0000-0003-3905-4615)
- Jian He (ORCID: https://orcid.org/0000-0001-8140-4610)
- Dongsheng Chen (ORCID: https://orcid.org/0009-0003-8626-9827)
- Yi Sun (ORCID: https://orcid.org/0000-0002-3818-1260)
- Hao Cheng (ORCID: https://orcid.org/0000-0001-6621-7614)
- Huizi Sha (ORCID: https://orcid.org/0000-0001-6820-8885)
- Jiayao Ni (ORCID: https://orcid.org/0009-0004-4845-3006)
- Shanshan Shen (ORCID: https://orcid.org/0009-0000-7889-5674)
- Yudong Qiu (ORCID: https://orcid.org/0009-0007-8227-9322)
- Xiaoxuan Wang (ORCID: https://orcid.org/0009-0006-2844-318X)
Institutions
- Nanjing University of Chinese Medicine (CN)
- National Medical Products Administration (CN)
- Nanjing University of Science and Technology (CN)
- Simcere Pharmaceutical (China) (CN)
- Nanjing Drum Tower Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- State Key Laboratory of Chemical Engineering (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2461
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00